ArticleVirchows Archiv : an international journal of pathology2015
Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer.
Article in Virchows Archiv : an international journal of pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 53 citations in OpenAlex.
- Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases.Human pathology · 2024Article
- Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma.Frontiers in pharmacology · 2024Review
- Precision Medicine in Bladder Cancer: Present Challenges and Future Directions.Journal of personalized medicine · 2023Review
- HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role.International journal of molecular sciences · 2023Review
- Urothelial Carcinoma: Divergent Differentiation and Morphologic Subtypes.Surgical pathology clinics · 2022Review
- Clinicopathological Review of Micropapillary Urothelial Carcinoma.Current oncology reports · 2022Review
- Molecular Pathology of Urothelial Carcinoma.Surgical pathology clinics · 2021Review
- Survivin and Her2 Expressions in Different Grades of Urothelial Neoplasms of Urinary Bladder.Iranian journal of pathology · 2021Article
- Frontiers in Bladder Cancer Genomic Research.Frontiers in oncology · 2021Review
- Expression of HER2 and Mismatch Repair Proteins in Surgically Resected Gallbladder Adenocarcinoma.Frontiers in oncology · 2021Article
- Combination of histological and molecular data for improving outcome prediction in non-muscle invasive bladder cancer-narrative review.Translational cancer research · 2020Review
- The prognostic role of steroid hormone receptor signaling pathways in urothelial carcinoma.Translational cancer research · 2020Review
- Prognostic and therapeutic role of HER2 expression in micropapillary carcinoma of the bladder.Molecular and clinical oncology · 2019Review
- Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.JCO precision oncology · 2019Article
- Updates on the Genetics and Molecular Subtypes of Urothelial Carcinoma and Select Variants.Surgical pathology clinics · 2018Review
- Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- Antibody-Drug Conjugates in Bladder Cancer.Bladder cancer (Amsterdam, Netherlands) · 2018Review
- Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.Human pathology · 2018Article
- Producing defucosylated antibodies with enhanced in vitro antibody-dependent cellular cytotoxicity viaEngineering in life sciences · 2017Article
- Contemporary update on neoadjuvant therapy for bladder cancer.Nature reviews. Urology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several (pre-) clinical trials are currently investigating the benefit of HER2-targeted therapy in urothelial bladder cancer (UBC). Patients with HER2 amplified UBC could potentially profit from these therapies. However, little is known about histomorphology, HER2 protein expression patterns and occurrence of alterations in the HER2 gene in their tumors. Among 150 metastasizing primary UBC, 13 HER2 amplified tumors were identified. Their histopathological features were compared with 13 matched, non-amplified UBC. HER2 protein expression was determined by immunohistochemistry. The 26 tumors were screened for mutations in exons 19 and 20 of the HER2 gene. UBC with HER2 amplification presented with a broad variety of histological variants (median 2 vs. 1), frequently featured micropapillary tumor components (77 % vs. 8 %) and demonstrated a high amount of tumor associated inflammation. Immunohistochemically, 10 of 13 (77 %) HER2 amplified tumors were strongly HER2 protein positive. Three tumors (23 %) were scored as HER2 negative. One of the HER2 amplified tumors harbored a D769N mutation in exon 19 of the HER2 gene; all other tested tumors were wild type. In conclusion, HER2 amplified UBC feature specific morphological characteristics. They frequently express the HER2 protein diffusely and are, therefore, promising candidates for HER2 targeted therapies. The detection of mutations at the HER2 locus might add new aspects to molecular testing of UBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.